MENU
+Compare
NTLA
Stock ticker: NASDAQ
AS OF
Jul 1, 11:16 AM (EDT)
Price
$9.35
Change
-$0.03 (-0.32%)
Capitalization
970.58M

NTLA Intellia Therapeutics Forecast, Technical & Fundamental Analysis

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics... Show more

Industry: #Biotechnology
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NTLA with price predictions
Jun 30, 2025

Aroon Indicator for NTLA shows an upward move is likely

NTLA's Aroon Indicator triggered a bullish signal on May 27, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 134 similar instances where the Aroon Indicator showed a similar pattern. In of the 134 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 12, 2025. You may want to consider a long position or call options on NTLA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on June 12, 2025. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

NTLA moved above its 50-day moving average on June 06, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NTLA crossed bullishly above the 50-day moving average on June 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where NTLA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NTLA broke above its upper Bollinger Band on June 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.244) is normal, around the industry mean (16.388). P/E Ratio (0.000) is within average values for comparable stocks, (58.437). NTLA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.308). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (20.747) is also within normal values, averaging (249.505).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NTLA is expected to report earnings to fall 6.36% to -102 cents per share on July 31

Intellia Therapeutics NTLA Stock Earnings Reports
Q2'25
Est.
$-1.03
Q1'25
Beat
by $0.17
Q4'24
Beat
by $0.07
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.30
The last earnings report on May 08 showed earnings per share of -110 cents, beating the estimate of -126 cents. With 353.03K shares outstanding, the current market capitalization sits at 970.58M.
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCEQX24.04N/A
N/A
Victory Pioneer Equity Income C
CISGX20.66N/A
N/A
Touchstone Sands Capital Select Gr Instl
FMDCX15.38N/A
N/A
Federated Hermes Mid-Cap Index Svc
HRLRX9.30N/A
N/A
Hartford Real Asset R3
IGAIX42.65N/A
N/A
American Funds Intl Gr and Inc F3

NTLA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.88%
VCYT - NTLA
69%
Closely correlated
-1.28%
CRSP - NTLA
65%
Loosely correlated
+4.15%
BEAM - NTLA
64%
Loosely correlated
+1.25%
RXRX - NTLA
56%
Loosely correlated
+0.70%
AXON - NTLA
55%
Loosely correlated
+1.14%
More